Priya Gor is an Oncology physician. OpenAlex indexes 6 publications with 229 citations (h-index 2); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1930 East Route 70
Suite V-107
Cherry Hill, NJ 08003
Telephone
856-424-7983Registry record last updated 6 May 2010.
Clinical trials
- Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy
Sponsor: Virtua Health, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20252 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
74.7%Other antiemetics69%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist5.7%Ondansetron hydrochloride95%Ondansetron Odt3%Ondansetron Hcl2%Part D + Part B<11 patientsCancer & immunology
21.6%Estrogen Receptor Antagonist14.8%Fulvestrant100%Part B, office-administered≥11 patientsAromatase Inhibitor5.6%Anastrozole74%Exemestane15%Letrozole12%Part D≥172 patients+ 3 more classes in this area
Musculoskeletal
2.7%Bisphosphonate2.7%Zoledronic acid100%Part B, office-administered≥47 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- QIM26-305: Central Fill Optimization to Reduce Drug Waste and Enhance Multidisciplinary Workflow Within an Ambulatory Infusion Suite
Journal of the National Comprehensive Cancer Network
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”